Benzinga | Sep 9, 2021 07:08AM EDT

GT Biopharma Announces Issuance Of Two New Patents Covering TriKE Platform Technologies

GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE(r) protein biologic technology platform, today announced that the United States Patent and Trademark Office (USPTO) has issued 2 new patents:

2 Patent No. 11,098,100 -- Broad coverage for TriKE proteins targeting any antigen

4 Patent No. 11,098,101 -- Broad coverage for TriKE proteins targeting HIV antigens

These two patents cover the Company's pipeline of clinical and non-clinical product candidates consisting of tri-specific killer engagers, or TriKEs, designed to target natural killer, or NK, cells and tumor or virus infected cells forming an immune synapse between the NK cell and the tumor cell thereby inducing NK cell activation at that site. The patents broadly include TriKEs that target the CD16 receptor, which includes the more potent camelid nanobody sequence, an IL-15 activating domain and any targeting domain, including but not limited to B7H3, PDL1, CLEC12A, ROR1, CD33, CD133, CD20, CD19, HER2, EpCAM, EGFR, VEGF-A, mesothelin, and HIV.

"2021 has been an exciting year for GT Biopharma as we reported positive, interim data results from our first-in-human GTB-3550 TriKE(r) Phase I clinical trial for the treatment of refractory/relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). As such, we are delighted that these newly granted patents have secured the broad IP rights underpinning the TriKE(r) technology platform. The granting of these patents provide us the necessary protection to continue to expand our clinical development path forward," noted Anthony Cataldo, Chairman and CEO.